

Updated 21/01/2021



## Summary of treatments for men with intermediate or high risk prostate cancer suitable for radical and focal therapy

| Type of treatment               | Mechanism  | Number<br>sessions                 | Urine<br>leakage<br>(any<br>pad<br>use) | Urinary<br>symptoms<br>(frequency,<br>nocturia,<br>urgency) | Erectile<br>dysfunction | Dry<br>orgasm | Back-<br>passage<br>symptoms | Rectal<br>injury | Need for<br>another<br>type of<br>cancer<br>treatment<br>(5-10 years) | Need for<br>another type<br>of cancer<br>treatment<br>(10 -15years) | Cancer-<br>specific<br>survival<br>(5-10 years) | Cancer specific<br>survival<br>(10-15 years) |
|---------------------------------|--|------------------------------------|---|---|-------------------------|---------------|------------------------------|------------------|---|---|---|--|
| Prostatectomy                   | Whole<br>prostate<br>removal<br>using surgery            | Once                               | 10-25%                                  | 5-15%   | 30-60%                  | 100%          | 1%                           | Rare             | 5-10%   | 10-15%  | 99-100%   | >97%   |
| Radiotherapy<br>(external beam) | Whole prostate from outside                              | 20 to 37<br>weekdays               | 5%                                      | 5-15%   | 30-60%                  | 100%          | 5-15%                        | Rare             | 5-10%   | 10-15%  | 99-100%   | >97%   |
| Radiotherapy<br>(brachytherapy) | Whole<br>prostate<br>irradiation<br>from inside          | Once                               | 5%                                      | 5-15%   | 30-60%                  | 100%          | 5%                           | Rare             | 5-10%   | 10-15%  | 99-100%   | >97%   |
| Focal Therapy                   | Heat (HIFU)<br>or freeze<br>(cryotherapy)<br>cancer area | 70-80%<br>once.<br>20-30%<br>twice | 1-2%                                    | 5%  | 5-20%                   | 50%           | <1%                          | Rare             | 5-10%   | Not known   | 99-100%   | Not known                                    |

These are overall estimates based on a number of sources. Specific rates for each patient may be different and quoted as such by clinicians depending on baseline risk Radical Therapy data based on PROTECT RCT, CHIPP trial and UK National Prostate Cancer Audit Focal Therapy data based on UK HEAT and UK ICE registry approved by UK NICE and published 2018/2019 Publications available on request

Imperial Prostate Imperial College Healthcare NHS Trust & Imperial College London imperial.prostate@nhs.net